Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone
In this study involving patients with fibrous dysplasia of bone, denosumab was associated with marked reductions in the serum bone markers and with bony improvement. However, rebound hypercalcemia occurred. A study published in the New England Journal of Medicine, February 2023.
Luis F. de Castro, Ph.D.
Zachary Michel, B.S.
Kristen Pan, M.D.
Jocelyn Taylor, B.S.
Vivian Szymczuk, M.D.
Sriram Paravastu, B.S.
Babak Saboury, M.D., M.P.H.
National Institutes of Health, Bethesda, MD
Georgios Z. Papadakis, M.D., Ph.D.
Foundation for Research and Technology, Heraklion, Greece
Xiaobai Li, Ph.D.
Kelly Milligan, R.N.
National Institutes of Health, Bethesda, MD
Brendan Boyce, M.B., Ch.B.
University of Rochester Medical Center, Rochester, NY
Scott M. Paul, M.D., M.P.H.
Michael T. Collins, M.D.
Alison M. Boyce, M.D.
National Institutes of Health, Bethesda, MD
